Biogen Reports Positive Phase 2 Results for Skin Lupus Treatment
Biogen announced positive results from its Phase 2 trial for an experimental drug treating cutaneous lupus erythematosus, a skin condition. Clearance rates for participants improved over a full year of treatment, with 27% of participants achieving this outcome.